Corporate ActionMay 20, 2026, 04:24 PM
Annovis Bio Prices $15M Public Offering of Stock and Warrants
AI Summary
Annovis Bio, Inc. announced the pricing of a public offering, issuing 7,895,000 shares of common stock and accompanying warrants to purchase up to 7,105,500 shares. The combined offering price for each share and nine-tenths of a warrant is $1.90, expected to generate approximately $15 million in gross proceeds. The company intends to use the net proceeds to advance the clinical development of its lead compound, Buntanetap, for Alzheimer's and Parkinson's diseases, and for general corporate purposes. The offering is anticipated to close around May 21, 2026.
Key Highlights
- Priced public offering of 7,895,000 shares of common stock.
- Issued accompanying warrants to purchase up to 7,105,500 shares of common stock.
- Combined offering price of each share and accompanying warrant is $1.90.
- Warrants are immediately exercisable at $2.25 per share and expire in six years.
- Expected gross proceeds from the offering are approximately $15 million.
- Net proceeds will fund clinical development of Buntanetap for Alzheimer's and Parkinson's disease.
- Funds also allocated for working capital and general corporate purposes.
Price Impact
More from ANVS